These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10618274)

  • 21. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group.
    Modlin JF; Halsey NA; Thoms ML; Meschievitz CK; Patriarca PA
    J Infect Dis; 1997 Feb; 175 Suppl 1():S228-34. PubMed ID: 9203721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants.
    Migasena S; Simasathien S; Samakoses R; Pitisuttitham P; Sangaroon P; van Steenis G; Beuvery EC; Bugg H; Bishop R; Davidson BL
    Vaccine; 1995 Feb; 13(2):168-74. PubMed ID: 7625111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.
    Onorato IM; Modlin JF; McBean AM; Thoms ML; Losonsky GA; Bernier RH
    J Infect Dis; 1991 Jan; 163(1):1-6. PubMed ID: 1845806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and fecal poliovirus excretion in sequential use of inactivated and oral poliovirus vaccines.
    Lu CY; Kao CL; Lee CY; Lee PI; Huang LM
    J Formos Med Assoc; 2001 Aug; 100(8):513-8. PubMed ID: 11678000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
    Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G; Hazendonk T; Beuvery C
    Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
    Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
    Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules.
    Parent du Châtelet I; Merchant AT; Fisher-Hoch S; Luby SP; Plotkin SA; Moatter T; Agboatwalla M; McCormick JB
    Vaccine; 2003 Apr; 21(15):1710-8. PubMed ID: 12639494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.
    Yakovenko ML; Cherkasova EA; Rezapkin GV; Ivanova OE; Ivanov AP; Eremeeva TP; Baykova OY; Chumakov KM; Agol VI
    J Virol; 2006 Mar; 80(6):2641-53. PubMed ID: 16501074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines.
    Hanson LA; Carlsson B; Jalil F; Lindblad BS; Khan SR; van Wezel AL
    Rev Infect Dis; 1984; 6 Suppl 2():S356-60. PubMed ID: 6740073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.
    Xiao Y; Daniell H
    Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
    Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
    Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of different strategies of vaccine prophylaxis for poliomyelitis in the Ukraine].
    Moĭseieva HV; Zadorozhna VI
    Lik Sprava; 2002; (2):85-8. PubMed ID: 12073271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine.
    Modlin JF; Onorato IM; McBean AM; Albrecht P; Thoms ML; Nerhood L; Bernier R
    Am J Dis Child; 1990 Apr; 144(4):480-4. PubMed ID: 2157337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
    Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
    J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
    Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
    J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.